- Overview
- 150 Years
- News
- Biographies
- Speeches
- Photos
- TV Footage
- Publications
- Video Center
- Social Media Channels
- Apps
- Events
- Stories
- Media Contact
News
Tuesday - May 21, 2013Novel ideas for mobility, construction and IT:
Bayer opens Innovation Hub for Asia Pacific
More than 200 experts to be employed in Shanghai more
Monday - May 20, 2013
Not intended for U.S. and UK Media - American Thoracic Society International Conference, Philadelphia, USA:
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) more
Not intended for U.S. and UK Media - American Thoracic Society International Conference, Philadelphia, USA:
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) more
SPECIALIZED PRESS
Not intended for U.S. and UK Media
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan more
Thursday - May 16, 2013
Strategic move to strengthen Consumer Care business:
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast® and Laif® brands more
Strategic move to strengthen Consumer Care business:
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast® and Laif® brands more
Thursday - May 16, 2013
Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types more
Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types more
Wednesday - May 15, 2013
Not intended for U.S. and UK Media
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival more
Not intended for U.S. and UK Media
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival more
Wednesday - May 15, 2013Growing weed resistance drives demand for alternative technologies:
Bayer CropScience announces intention to construct a state-of-the-art facility for glufosinate-ammonium herbicide more
Wednesday - May 15, 2013Dr. Herbert Heitmann to be new Head of Communications and Government Relations at Bayer more
Publications
Events
Wednesday, July 31, 2013
Q2 2013 Interim Report
Additional Press Events
Investor Relations Events
BayKomm Events
Q2 2013 Interim Report
